MedPath

Oncotelic Inc.

Oncotelic Inc. logo
🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:0

Trial Phases

1 Phases

Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 2
3 (100.0%)

A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

Phase 2
Recruiting
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Drug: mFOLFIRINOX
First Posted Date
2023-10-12
Last Posted Date
2024-08-13
Lead Sponsor
Oncotelic Inc.
Target Recruit Count
455
Registration Number
NCT06079346
Locations
🇺🇸

Karmanos Cancer Center, Detroit, Michigan, United States

🇺🇸

Baylor College of Medicine, Houston, Texas, United States

OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition

Phase 2
Not yet recruiting
Conditions
Malignant Pleural Mesothelioma
Interventions
First Posted Date
2022-06-21
Last Posted Date
2024-03-15
Lead Sponsor
Oncotelic Inc.
Target Recruit Count
63
Registration Number
NCT05425576
Locations
🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects

Phase 2
Conditions
COVID-19
Interventions
First Posted Date
2021-03-16
Last Posted Date
2021-03-16
Lead Sponsor
Oncotelic Inc.
Target Recruit Count
18
Registration Number
NCT04801017
Locations
🇧🇷

Praxis Pesquisa Medica S / S Ltda, Jardim, Brazil

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.